Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cytisine versus nicotine replacement therapy for smoking cessation
ACTRN12610000590066Phase 3Completed
- Sponsor
- Health Research Council of New Zealand
- Start
- Mar 2011
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in nicotine dependence comparing Cytisine plus behavioral support with Nicotine replacement therapy plus behavioral support (2 arms). Primary endpoint: Continuous abstinence at 1 month. Started Mar 2011; status: completed.
02
Drugs
cytisiniclinenicotine patch
03
Conditions
nicotine dependence
Beyond the preview
Go deeper on ACTRN12610000590066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12610000590066.